鲁抗医药: 鲁抗医药关于向特定对象发行股票申请获得上海证券交易所审核通过的公告

Core Viewpoint - Shandong Lukang Pharmaceutical Co., Ltd. has received approval from the Shanghai Stock Exchange for its application to issue shares to specific targets, pending final registration approval from the China Securities Regulatory Commission (CSRC) [1] Group 1 - The company received the Shanghai Stock Exchange's review opinion on August 20, 2025, confirming that the application meets the issuance conditions, listing conditions, and information disclosure requirements [1] - The company must obtain approval from the CSRC before proceeding with the issuance of shares, and the timing and outcome of this approval remain uncertain [1] - The company commits to timely information disclosure in accordance with relevant laws and regulations regarding the issuance of shares to specific targets [1]